Pulmonary Perfusion Heterogeneity in Patients With CTEPH Using Functional PET Imaging
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02114047
Recruitment Status :
First Posted : April 15, 2014
Last Update Posted : March 23, 2017
Massachusetts General Hospital
Information provided by (Responsible Party):
Robert Scott Harris, M.D., Massachusetts General Hospital
This study with evaluate blood flow in the lungs of patients prior to and after surgery for treatment.
Condition or disease
Chronic Thromboembolic Pulmonary Hypertension
Specifically, we will evaluate the length-scale or size of blood flow alterations using filtering techniques with the objective of identifying the size of blood vessels that are obstructed by clot (large vessels versus small vessels).
We will use a method to analyze the length-scale of perfusion heterogeneity before and after surgery for CTEPH. Briefly, this method consists of filtering the images with filters of different spatial size (length, mm) and measuring the coefficient of variation (CV) of perfusion in the imaged field. We then bin the CV into the following intervals: 12-36 mm, 36-60 mm, 60-84 mm, 84-108 mm and >108 mm and compare the CV in each bin among subjects.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Chronic thromboembolic pulmonary hypertension
Subject is diagnosed with chronic thromboembolic pulmonary hypertension (WHO Group IV) and planning to undergo pulmonary thromboendarterectomy.
Subject is male or female aged > or =18 years of age and < or = 70 years.
Subject has undergone RHC within six months of entering the study.
The subject is capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
A signed and dated written informed consent is obtained from the subject.
Available to complete the study.
Able to lie flat and able to perform a 30 second breath hold.
FEV1 and/or TLC < 70% predicted.
Inability to perform the study (by primary MD or investigator assessment).
Inability to perform the respiratory maneuvers necessary for the exam.
Subjects who have a past or present disease, which as judged by the Investigators may affect the outcome of this study.
The subject has suspected history of drugs or alcohol abuse within the six months prior to the screening visit.
The subject is a woman of childbearing potential who is pregnant, seeking to become pregnant, or has a positive pregnancy test.
Subject with clinical instability in the judgment of the investigator, with a heart rate > 120 bpm, respiratory rate > 24, SpO2 < 88%, blood pressure < 90/60 or > 140/90 or fever > 101, or subjects with hospitalization for progression of pulmonary hypertension or right heart failure in the three months prior to the study.
Subject with diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, allergic rhinitis, asthma, heart failure, ischemic heart disease, or COPD.
Subject that had a respiratory tract infection in the 4 weeks prior to the screening visit and throughout the duration of the study.
The subject has been exposed to a radiation dose over the past year that, when added to the radiation dose expected in this study, would exceed permissible yearly exposure as determined by the MGH radiation safety committee.